Journal Based CME - Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions

The treatment metastatic non-small cell lung cancer (NSCLC) is largely influenced by the incorporation of immune checkpoint inhibitors (ICI) in the frontline setting. There are several ICI approved for the management of NSCLC based on the PD-L1 expression of the tumors. PD-L1 is a controversial biomarker with various inconsistencies in expression owing to temporal and spatial heterogeneity. Tumor mutational burden is another much studied biomarker associated with its own challenges and questionable concordance with tumor PD-L1 expression. In this article, we aim to discuss the challenges associated with the existing biomarkers, highlighting the need for emerging biomarkers that can help with decision making in the management of this there where several therapeutic options exist.  There are emerging “me too” PD-1/PD-L1 drugs which may serve its purpose in many counties where there is limited access to current approved ICIs. What is increasingly apparent is the need to move the needle forward in the treatment of NSCLC and we will discuss the challenges associated with the current therapeutic landscape and the emerging checkpoints and the future directions that are being explored in the management of metastatic NSCLC.

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($0.00)

If you are a healthcare provider involved in patient care and you are not employed by the Industry, register for free!

 

 

Target Audience

  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Researchers and others involved in the care of cancer patients

Learning Objectives

Upon successful completion of this journal-based continuing education activity, participants will be able to:

  • Identify the challenges associated with the current therapeutic landscape and the emerging checkpoints and the future directions that are being explored in the management of metastatic NSCLC.

Additional Information

AttachmentSize
File ImmuneCheckpointInhibitors_Biomarker_Revised_notrack (1)_0.docx215.07 KB
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 1.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.00 Contact Hours.
Course opens: 
03/23/2023
Course expires: 
03/26/2024
Cost:
$0.00

This is a journal based continuing education activity. Please read the following article in the International Journal of Cancer Care and Delivery and login to your account on this site to claim credit. ''Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions'' 

 

link to article here

FACULTY

Arthi Sridhar, MD - author

Pawan Kumar Singh - author 

Kaushal Parikh - author

No members of this activity's planning committee or faculty have any relevant financial relationship with an ineligible entity.

All relevant financial relationships of individuals in control of the content have been identified and mitigated.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 1.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.00 Contact Hours.

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($0.00) 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, register for free!

CANCELLATION POLICY

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.

REFUND POLICY 

This activity is free for all healthcare providers who are not employees of an ineligible entity.

No refunds will be issued.